All In Biotech

Drug Trial Radar · NCT02455622

Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age

A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients With MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Years of Age

Last checked: Nov 20, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

21

Actual

Start

Oct 28, 2015

Primary completion

Jul 29, 2025

Study completion Jul 29, 2025

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
Collaborators
Takeda Development Center Americas, Inc.
First posted
May 28, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This long-term study will provide Elaprase treatment to children enrolled in this study and will utilize data from both enrolled patients and Hunter Outcome Survey (HOS) patient registry data to conduct the primary growth analysis to assess changes in height and weight in patients with Mucopolysaccharidosis II (Hunter syndrome) MPS II.

Conditions

  • Hunter Syndrome

Interventions

  • Elaprase for intravenous (IV) infusionDrug

    Patients enrolled in this study will receive once-weekly IV infusions of Elaprase at a dose of 0.5 mg/kg and will be followed for a minimum of 5 years after initiation of Elaprase treatment, or until they reach their 10th birthday, whichever is longer.Height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Height OverallTime frame: Prospective participants: From Baseline through End-of-Study (approximately 9.75 years); HOS participants followed up to a maximum of 9.5 years where participant data were accessed from the registry between the period of 08/01/07 to 02/06/22
  2. Weight OverallTime frame: Prospective participants: From Baseline through End-of-Study (approximately 9.75 years); HOS participants followed up to a maximum of 9.5 years where participant data were accessed from the registry between the period of 08/01/07 to 02/06/22
  3. Change From Baseline in Height Measured by Z-scoreTime frame: Prospective participants: From Baseline through End-of-Study (approximately 9.75 years); HOS participants followed up to a maximum of 9.5 years where participant data were accessed from the registry between the period of 08/01/07 to 02/06/22
  4. Change From Baseline in Weight Measured by Z-scoreTime frame: Prospective participants: From Baseline through End-of-Study (approximately 9.75 years); HOS participants followed up to a maximum of 9.5 years where participant data were accessed from the registry between the period of 08/01/07 to 02/06/22
  5. Number of Participants With Clinical Significant Abnormal Neurological ExaminationTime frame: From Screening to End-of-Study (approximately 9.75 years)
  6. Number of Participants With Treatment-emergent Adverse Events (TEAE)Time frame: From screening to End-of-Study (approximately 9.75 years)
  7. Number of Participants With Clinically Significant Abnormal Urinalysis ValuesTime frame: From screening to End-of-Study (approximately 9.75 years)
  8. Number of Participants With Clinically Significant Abnormal Serum Chemistry ValuesTime frame: From screening to End-of-Study (approximately 9.75 years)
  9. Number of Participants With Clinically Significant Abnormal Hematology ValuesTime frame: From screening to End-of-Study (approximately 9.75 years)

Locations

8 sites in 8 countries. Site status is shown where the registry gives one.

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Hospital Infantil Dr Robert Reid Cabral

    Santo Domingo, Dominican Republic

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz

    Mainz, Germany

  • Hospital Kuala Lumpur

    Kuala Lumpur, Malaysia

  • Philippine General Hospital

    Manila, Philippines

  • Mother and Child Health Care Institute of Serbia Dr Vukan Cupic

    Belgrade, Serbia

  • Chulalongkorn University

    Bangkok, Thailand

  • National Pediatrics Hospital

    Hanoi, Vietnam

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.